Premium
Smoking adversely affects survival in acute myeloid leukemia patients
Author(s) -
Varadarajan Ramya,
Licht Andrea S.,
Hyland Andrew J.,
Ford Laurie A.,
Sait Sheila N.J.,
Block Annemarie W.,
Barcos Maurice,
Baer Maria R.,
Wang Eunice S.,
Wetzler Meir
Publication year - 2011
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.26151
Subject(s) - medicine , univariate analysis , myeloid leukemia , cytarabine , white blood cell , multivariate analysis , leukemia , hematopoietic stem cell transplantation , oncology , transplantation
Smoking adversely affects hematopoietic stem cell transplantation outcome. We asked whether smoking affected outcome of newly diagnosed acute myeloid leukemia (AML) patients treated with chemotherapy. Data were collected on 280 AML patients treated with high‐dose cytarabine and idarubicin‐containing regimens at Roswell Park Cancer Institute who had smoking status data at diagnosis. Patients' gender, age, AML presentation ( de novo vs . secondary), white blood cell (WBC) count at diagnosis, karyotype and smoking status (never vs . ever) were analyzed. Among the 161 males and 119 females with a median follow‐up of 12.9 months, 101 (36.1%) had never smoked and 179 (63.9%) were ever smokers. The proportion of patients between never and ever smokers was similar to respect to age, AML presentation, WBC count at diagnosis or karyotype based on univariate analysis of these categorical variables. Never smokers had a significantly longer overall survival (OS) (60.32 months) compared to ever smokers (30.89; p = 0.005). In multivariate analysis incorporating gender, age, AML presentation, WBC count, karyotype and smoking status as covariates, age, karyotype and smoking status retained prognostic value for OS. In summary, cigarette smoking has a deleterious effect on OS in AML.